US20050020996A1 - Method and apparatus to control drug therapy dosages in an implantable pump - Google Patents
Method and apparatus to control drug therapy dosages in an implantable pump Download PDFInfo
- Publication number
- US20050020996A1 US20050020996A1 US10/921,015 US92101504A US2005020996A1 US 20050020996 A1 US20050020996 A1 US 20050020996A1 US 92101504 A US92101504 A US 92101504A US 2005020996 A1 US2005020996 A1 US 2005020996A1
- Authority
- US
- United States
- Prior art keywords
- drug
- patient
- controller
- dosage
- bolus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G05—CONTROLLING; REGULATING
- G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
- G05B19/00—Programme-control systems
- G05B19/02—Programme-control systems electric
- G05B19/04—Programme control other than numerical control, i.e. in sequence controllers or logic controllers
- G05B19/10—Programme control other than numerical control, i.e. in sequence controllers or logic controllers using selector switches
- G05B19/106—Programme control other than numerical control, i.e. in sequence controllers or logic controllers using selector switches for selecting a programme, variable or parameter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M2005/1401—Functional features
- A61M2005/1405—Patient controlled analgesia [PCA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M2005/14208—Pressure infusion, e.g. using pumps with a programmable infusion control system, characterised by the infusion program
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3507—Communication with implanted devices, e.g. external control
- A61M2205/3523—Communication with implanted devices, e.g. external control using telemetric means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
Definitions
- This invention relates to implantable drug infusion pumps.
- this invention relates to a method and apparatus for controlling drug dosages that can be delivered by an implantable drug infusion pump.
- Implanted infusion pumps deliver therapeutic drugs to a patient according to a computer program executed by a processor that is programmed with drug dosing parameters.
- a microprocessor controls a small, positive displacement pump according to programming instructions delivered to the microprocessor through an RF programming link so as to permit the implantable pump to be remotely programmed and operated.
- the processor controls a mechanical pump according to programmed dosage parameters.
- a problem with prior art drug infusion pumps are that they run open-loop, i.e. there is no feedback mechanism controlling drug dosing.
- implantable infusion pumps need to permit the patient to self-administer a bolus of medication on demand.
- many diabetics need to administer a bolus of insulin either just prior to or just after a meal.
- the changing of drug infusion rates is important as the insulin requirements of diabetic patients' change during the course of a day. Therefore, it is important that any drug treatment system be able to accommodate a predetermined constant delivery rate as well as any adjustments that may be required during the course of a day.
- this frequent changing of dosage rates can lead to potential underdosing or overdosing situations.
- a remotely programmable and implantable tissue stimulator is disclosed in U.S. Pat. No. 5,443,486 to Hrdicka et al., for a “Method and Apparatus to Limit Control of Perimeters of Electrical Tissue Stimulators.” While the '486 Patent discloses a remotely programmable tissue stimulator and permits the patient to control the administration of tissue stimuli, the device disclosed in the '486 patent does not provide for programmable drug infusion therapy. Nor does the '486 provide for software-based drug infusion limits.
- Programmable infusion limits in implantable infusion pumps might lessen the likelihood that a patient will overdose or underdose himself. Moreover, a software-defined limit might also lessen the likelihood that certain drug regimens will be used improperly—even by health-care providers. By using a software-defined drug dosage limit, pump manufacturers might specify certain maximum and minimum dosages for certain disorders by pre-programming their own infusion pumps with the drug dosage limitations.
- implanted drug infusion pumps require limits to be placed upon the drug delivery amount and/or frequency by health care professionals.
- An internal limit on the amount by which a patient can self-dose a drug would be an improvement over the prior art implantable infusion pumps. Similar limits might prevent health care providers from inadvertently overdosing, or even underdosing treatments.
- a fully implantable drug infusion pump which includes an RF programming link, an implantable drug reservoir wherein a therapeutic drug is stored and a small, microprocessor-controlled positive displacement pump is entirely software controlled using an embedded and implantable microprocessor and power supply.
- Programming instructions and data delivered to the microprocessor through an RF programming link are used to limit infused drug dosage.
- the dosage limit data is stored in programmable memory within the microprocessor or in separate memory devices.
- the microprocessor controlling drug administration compares the amount of drug administered over time according to the data parameters defining the treatment regimen's dosage limits.
- the programmable infusion pump also permits the patient to self-administer additional doses on demand.
- the patient-requested additional dosage limits are specified by the patient's health care provider and these limits can be programmed into the implantable pump by the health care provider using the RF programming link. Thereafter, access to the dosage limits is not available to the patient.
- RF programming, data encryption or other security software could limit access to the drug dosage limit data.
- patients would have the flexibility to adjust the delivery of dosages to account for meals or needed bolus flow rates during the course of the day. These changes to the base flow would be tracked by a therapy program and compared to the dosage limits. Patient notification, for example through an alarm, may be utilized if the actual dosage would fall above or below the programmed dosage limits.
- Patient-controlled drug dosage is limited by the health care provider-specified limit value.
- drug manufacturers might offer implantable infusion pumps for use with certain drugs that have precise treatment regimens. Over-dosing or under-dosing might be precluded by way of dosing definitions programmed into secure data storage locations.
- underdosage by the patient could be avoided if the pump is programmed to a minimum dosage or by warning the patient.
- the warning could be an audio alarm from the pump or an indicator on the patient's controller to which the patient could respond by increasing the dosage.
- the same underdosage alarm could be implemented to alert the patient of a requested overdosage, thereby alerting the patient when a dosage request amounts to an overdosage not allowed by the pump.
- FIG. 1 discloses a simplified block diagram of an implantable, software controlled infusion pump providing software dosage limits.
- FIG. 2 shows a full system implementation of a pump including, the pump, a catheter, two external controllers, one patient use and one medical person use.
- FIG. 3 shows a diagrammatic view illustrating a patient controller and a physician programmer and their communication with an implantable drug pump.
- FIG. 4 illustrates a method of decreasing drug use in accordance with an embodiment of the invention.
- FIG. 5 illustrates a method of preventing drug underdosage in accordance with an embodiment of the invention.
- FIG. 6 illustrates a method of reducing the number of episodes requiring dose activations in accordance with an embodiment of the invention.
- FIG. 7 illustrates a method of preventing a drug overdose in accordance with an embodiment of the invention.
- FIG. 1 shows a simplified block diagram of the functional elements of an implantable and programmable drug infusion pump 100 having re-programmable (i.e. software-specified) dosage limits.
- the functional elements of the infusion pump 100 shown in FIG. 1 are small, such that the pump can be readily implanted into the abdomen of a patient for purposes of controlling chronic diseases, such as diabetes.
- An implanted infusion pump might also be used for acute treatment regimens, e.g. to administer chemotherapy drugs or morphine to treat cancer or treat pain respectively.
- a reservoir 102 contains some appropriate volume of drug to be administered to the patient by a pump 104 , preferably a precision positive displacement pump drawing drug material from the reservoir 102 .
- a pump 104 preferably a precision positive displacement pump drawing drug material from the reservoir 102 .
- FIG. 1 shows only a single reservoir and a single pump, the invention disclosed herein is readily adapted for use with multiple reservoirs for administering several different drugs or for increasing the volume of a single drug that might be implanted into the patient.
- Multiple pumps might be also used with multiple reservoirs to administering different drugs at different rates and times. Multiple pumps might be used with a single reservoir for increased reliability.
- the pump 104 is operatively coupled to and responsive to electrical signals delivered to it from a control unit 106 .
- Electrical signals from the control unit 106 would, for example, start and stop the pump 104 and including its delivery rate so as to modulate the delivery of drugs from the reservoir 102 to the patient.
- the control circuitry within the control unit 106 would typically include appropriate electronic drive circuits, the essential function of which is to couple a central processor 108 to the pump 104 through appropriate interface circuitry well know to those skilled in the art.
- Alternate embodiments of the invention would of course include implementing any required pump/CPU interface directly into the microprocessor, or selecting and/or designing the pump 104 to eliminate the need for an interface between it and the low power circuits of the microprocessor.
- Many commercial grade microprocessors include a plethora of ancillary circuitry on a single substrate including analog-to-digital converters, digital-to-analog converters, counters, timers, clocks and so forth.
- the central processor unit 108 controls the amount of drug treatment administered to the patient according to the therapy program instructions stored in a program memory 110 .
- the program memory which could be resident on the same semiconductor substrate as the CPU, typically requires the ability to temporarily store and retrieve data. Random access memory 112 shown in FIG. 1 and well known to those skilled in the art, is available for use by the program executed by the CPU 108 .
- ROM read-only-memory
- EPROM electrically programmable read only memory
- EEPROM electrically erasable programmable read-only memory
- the EPROM 114 and the EEPROM 116 are re-programmable semi-conductor memories as those skilled in the art will recognize.
- EEPROM 116 is particularly useful in the invention as it readily lends itself as a repository for drug therapy dosage characteristics and is safer than RAM (random access memory) because RAM is volatile and susceptible to errors caused by power source interruption.
- EEPROM retains data for long periods of time yet is readily re-programmed by the CPU.
- Many commercially available microprocessors include addressable EEPROM directly on the substrate comprising the CPU further simplifying the implementation of a software-limited dosage implantable drug infusion device.
- FIG. 2 shows the pump system embodiment including a drug infusion pump 200 and a drug infusion catheter 204 , suitable to deliver drugs to a distal sight in the body.
- Two external controllers are shown, one for patient use 210 and one for medical person use 220 .
- the pump 200 with the connected catheter 204 is implanted in the patient's body 216 under the skin 214 .
- RF energy 212 flows bi-directionally between the pump 200 and the patient use external controller 210 .
- the health care provider uses an external controller 220 to independently program the implanted pump to the desire infusion parameters as is commonly done in the art.
- the manufacturer of the controller 220 sets the range of controller 220 .
- a piezoelectric transducer or other suitable audio enunciator 202 on the pump body or otherwise electrically coupled to the pump and its internal controller might be used to provide an audible alarm to the patient in the case of under or overdosing.
- a health care provider programs the implantable infusion pump 100 using a remote programming device 210 , such as the programming device disclosed in U.S. Pat. No. 5,443,486 and U.S. Pat. No. 4,676,248, “Circuit for Controlling a Receiver in an Implanted Device” by Berntson.
- the program executed by the CPU 108 regularly scans the RF link (embodied by the programming control 120 and the uplink telemetry 122 ) for commands. Alternate embodiments would of course include RF communication link circuits that assert an interrupt control line on so-equipped processors.
- At least one command recognizable by the CPU 108 is a patient-initiated request to the pump 100 to administer a bolus of drug from the reservoir 102 .
- Such a request would be sent to the pump 100 by the patient being provided with a transponder specifically designed to transmit a bolus-request command.
- the functionality of the patient-operated device 210 is limited and incapable of altering key data programmed by a health care provider.
- Both the health-care provided instructions and the patient requested doses are delivered to the CPU 108 through an input port on the CPU.
- Such an input port of the CPU 108 would include a memory mapped input/output device or other parallel or appropriate buffered serial input port, all of which are commonly found on many commercially available micro controllers.
- the health care professional can specify a dose infusion characteristic parameter to be stored into one or more of the memory locations 124 , 126 and 128 of the memory device 109 depicting FIG. 1 .
- the dose infusion characteristic stored in memory may be one or more bytes of data (recognizable by the program instructions) to limit the amount, frequency, or other characteristic(s) of a dose of the drug to be administered to the patient by the pump 100 .
- the dose infusion characteristics could also prescribe dosage minimum dosage amounts as well.
- the dose infusion characteristic stored in one of the memory locations ( 124 , 126 , 128 ) in FIG. 1 could be used by the program stored in ROM 110 to limit the number of drug bolus deliveries that a patient may initiate in a twenty-four hour period.
- the drug dose infusion characteristic might control the volume of drug to be delivered upon the request of the patient over a given period of time.
- the bolus frequency, bolus dosage size per unit time, bolus size, or other dose information might also be stored.
- a drug dose infusion characteristic might be programmed into one of the memory locations 124 , 126 and 128 as fail-safe limits to prevent overdosing or underdosing a patient by a health care professional.
- Such an upper-limit of a drug dose might be used by the program in ROM 110 or EPROM 114 , 116 as a fail safe to prevent a health care professional from accidentally overdosing or underdosing the patient.
- the health care professional programs the infusion pump via the RF programming link.
- the CPU 108 might scan or poll sensors (not shown) providing data on the efficacy of the treatment. Alternate dosages might be indicated by input from one or more sensors. Dose limits would still provide a means by which maximum or minimum treatments would not be exceeded.
- controller 108 is preferably a programmable microcontroller or microprocessor.
- Such devices are well known in the electronics art and many include read-only memory, random access memory, EPROM and EEPROM on board the device.
- Such devices also routinely include a/d converters, d/a converters, counters, timers, and other circuits usable in a real time control application including an implantable infusion pump.
- Altering embodiments might include combinational as well as sequential logic although those skilled in the art will recognize the inherent advantages of using a microprocessor or micro controller. Still other embodiments would contemplate using analog devices, such as an analog computer to control the pump 104 in response to bodily conditions.
- Program instructions for the controller 108 are stored an appropriate memory device.
- Program instructions might also be stored in ROM, RAM, EPROM or EEPROM as set forth above.
- Infusion limits or dose characteristics are preferably stored in a programmable memory location, such as EPROM or EEPROM because of their ability to retain data over long periods of time, even if power is lost.
- RAM random access memory
- a health care professional would preferably download programming and/or data into the memory device 109 through the RF interlink circuitry 120 and 122 . As shown in FIG. 1 , these programming instructions and/or data have passed through the central processing unit 108 . Depiction of this data path in FIG. 1 should not be construed as limiting. Sufficient intelligence might be built into the RF link circuitry to directly load random access memory or other memory devices 109 directly through the programming link.
- FIG. 3 represents an alternative embodiment to the configuration of the patient controller 310 and the physician programmer 320 .
- the patient controller 310 contains a therapy program 306 for possible drug infusion rate adjustments.
- the patient controller 310 also contains a microprocessor 318 and memory 326 that would store treatment information such as base rate drug flows, the maximum and minimum daily allowable doses, patient activation requests, and drug delivery monitoring data.
- the health care provider would use the physician programmer 320 to specify the drug infusion characteristics that may include the maximum and minimum daily allowance dosages, 24 hour rolling average rate limits, nominal dosage rates, and a minimum time interval between bolus requests. In particular, the health care provider may program two or more different base infusion rates that would be acceptable in reaching the daily dosages.
- the nominal dosage rates would be the default rates and a patient could then select a different base rate using the patient controller 310 depending on the needed amount of therapy at any given time of the day.
- the patient controller 310 through the therapy program 306 would only allow a base rate change to those rates already approved by the health care professional.
- the patient controller 310 may also contain a notification mechanism to provide feedback to the patient.
- the patient controller 310 may contain an audio speaker 302 and a LCD display 304 to provide the patient with alarm, status and task information.
- the alarm information would be generated from the changes in the patient controller therapy program output.
- FIGS. 4, 5 , 6 , and 7 A brief overview of some of the steps that the therapy program would perform in determining whether the proper amount of drugs are being administered are shown in FIGS. 4, 5 , 6 , and 7 . These steps generally track drug infusion characteristics and allows the patient to adjust the therapy to provide a more efficient and effective drug treatment.
- FIG. 4 illustrates the steps that may be performed by the therapy program to determine whether the amount of drug being administered should be decreased. This may occur, for example, when the patient is not administering any additional bolus of drug, thereby suggesting that the base rate could possibly be reduced.
- the therapy program determines whether the patient has requested a dose of medication in a specified period of time. This dose request by the patient could be either a bolus dose or an increase in the base rate. The specified period of time would depend on the type of drug being administered and may be, for example, based one or more days or one or more hours. If the patient has requested dose activation within the specified period of time, then the program does not make any changes, at step 404 .
- the drug therapy could be reduced. Either the patient would be prompted, by the notification mechanism, to use the patient controller to select the next lowest base rate to reduce drug usage, or the therapy program could activate the smallest programmed dose when the patient makes an activation request.
- FIG. 5 illustrates the steps that may be performed by the therapy program to prevent drug underdosage.
- the therapy program determines whether a patient is nearing an underdosage condition.
- the program tracks the patient drug therapy and therefore, knows the actual total dosage being delivered to the patient.
- the actual total dosage delivered to the patient is the combination of the base rate and the number of bolus activations over the specified time period.
- the program also knows the minimum allowed dosage that is desired for a particular drug.
- the program compares the actual dosage and the minimum allowed dosage. If the actual dosage is within a predetermined percentage of the minimum allowed dosage then the patient is nearing an underdosage condition. This tracking of the total dosage allows flexibility in the administering of the drug therapy.
- the physician may prescribe a base rate over the course of a period of time below the minimum dosage with the knowledge that the patient will be administering a number of bolus dosages during that period of time. The combination of the base rate and the bolus dosage activations over the course of that time period would together reach the minimum allowed dosage. If the patient is not nearing an underdosage condition then the therapy program does not make any changes at step 504 . If, however, the therapy program determines that a patient is nearing an underdosage condition then the therapy program may prompt the patient, through the client notification system, to use the patient controller to either activate a bolus dose of medication or to use the next highest base rate as depicted in step 506 .
- FIG. 6 illustrates the steps that may be performed by the therapy program to determine whether the patient has requested too many bolus activations over a specified period of time.
- the therapy program determines whether the patient has requested more bolus activations than allowed by the health care provider. Because the program tracks the patient drug therapy, the program knows the number of bolus activations and bolus activation requests over a specified time period. If the number of bolus activations is below the allowable amount, then the therapy program continues in its normal fashion at step 604 . If, however, the patient has had more than the allowed number of drug bolus activations then the patient would be prompted by the notification mechanism to use the patient controller to select a higher base rate in an attempt to reduce the amount of future bolus activation requests.
- FIG. 7 illustrates the steps that may be performed by the therapy program to prevent a drug overdosage.
- step 702 it is determined whether the patient is currently utilizing the highest base rate allowed by the health care provider. Because the program tracks the patient drug therapy, the program knows the current base rate and the highest base rate programmed by the physician. If the patient is not at the highest base rate then the therapy program continues as normal at step 704 . However, if the base rate is at the highest allowable setting then the therapy program determines whether the patient is nearing his or her maximum daily dose at step 706 . If the patient is not nearing his or her maximum daily dose then the therapy program stops the inquiry and continues as normal at step 708 . However, if the patient is nearing the maximum daily dose then the therapy program could deny further activation requests, activate the smallest programmed dose when an activation request is made by the patient or prompt the patient to select the next lowest base rate.
Abstract
Description
- This application is a divisional of U.S. application Ser. No. 09/804,136 filed Mar. 12, 2001, which is a continuation-in-part of U.S. application Ser. No. 09/303,307 filed Apr. 30, 1999, the entire disclosures of which are hereby incorporated by reference.
- This invention relates to implantable drug infusion pumps. In particular, this invention relates to a method and apparatus for controlling drug dosages that can be delivered by an implantable drug infusion pump.
- Implanted infusion pumps deliver therapeutic drugs to a patient according to a computer program executed by a processor that is programmed with drug dosing parameters. A microprocessor controls a small, positive displacement pump according to programming instructions delivered to the microprocessor through an RF programming link so as to permit the implantable pump to be remotely programmed and operated. In the course of executing its program, the processor controls a mechanical pump according to programmed dosage parameters.
- A problem with prior art drug infusion pumps are that they run open-loop, i.e. there is no feedback mechanism controlling drug dosing. Moreover when used for treating many disorders, implantable infusion pumps need to permit the patient to self-administer a bolus of medication on demand. For example, many diabetics need to administer a bolus of insulin either just prior to or just after a meal. The changing of drug infusion rates is important as the insulin requirements of diabetic patients' change during the course of a day. Therefore, it is important that any drug treatment system be able to accommodate a predetermined constant delivery rate as well as any adjustments that may be required during the course of a day. However, this frequent changing of dosage rates can lead to potential underdosing or overdosing situations.
- While prior art implantable and programmable infusion pumps permit a patient to administer additional drug dosages on demand, these prior art devices do not adequately control the amount of patient-administered dosages increasing the likelihood that a patient may overdose or underdose himself, adversely affecting the patient's physician-prescribed therapy.
- A remotely programmable and implantable tissue stimulator is disclosed in U.S. Pat. No. 5,443,486 to Hrdicka et al., for a “Method and Apparatus to Limit Control of Perimeters of Electrical Tissue Stimulators.” While the '486 Patent discloses a remotely programmable tissue stimulator and permits the patient to control the administration of tissue stimuli, the device disclosed in the '486 patent does not provide for programmable drug infusion therapy. Nor does the '486 provide for software-based drug infusion limits.
- Programmable infusion limits in implantable infusion pumps might lessen the likelihood that a patient will overdose or underdose himself. Moreover, a software-defined limit might also lessen the likelihood that certain drug regimens will be used improperly—even by health-care providers. By using a software-defined drug dosage limit, pump manufacturers might specify certain maximum and minimum dosages for certain disorders by pre-programming their own infusion pumps with the drug dosage limitations.
- In order to lessen or prevent inadvertent infused drug overdoses or underdoses, implanted drug infusion pumps require limits to be placed upon the drug delivery amount and/or frequency by health care professionals. An internal limit on the amount by which a patient can self-dose a drug, would be an improvement over the prior art implantable infusion pumps. Similar limits might prevent health care providers from inadvertently overdosing, or even underdosing treatments.
- A fully implantable drug infusion pump, which includes an RF programming link, an implantable drug reservoir wherein a therapeutic drug is stored and a small, microprocessor-controlled positive displacement pump is entirely software controlled using an embedded and implantable microprocessor and power supply. Programming instructions and data delivered to the microprocessor through an RF programming link are used to limit infused drug dosage. The dosage limit data is stored in programmable memory within the microprocessor or in separate memory devices. The microprocessor controlling drug administration compares the amount of drug administered over time according to the data parameters defining the treatment regimen's dosage limits.
- In the preferred embodiment of the invention, the programmable infusion pump also permits the patient to self-administer additional doses on demand. The patient-requested additional dosage limits are specified by the patient's health care provider and these limits can be programmed into the implantable pump by the health care provider using the RF programming link. Thereafter, access to the dosage limits is not available to the patient. RF programming, data encryption or other security software could limit access to the drug dosage limit data. Within the therapy program limits, patients would have the flexibility to adjust the delivery of dosages to account for meals or needed bolus flow rates during the course of the day. These changes to the base flow would be tracked by a therapy program and compared to the dosage limits. Patient notification, for example through an alarm, may be utilized if the actual dosage would fall above or below the programmed dosage limits. Patient-controlled drug dosage is limited by the health care provider-specified limit value.
- In another embodiment, drug manufacturers, as well as health-care providers, might offer implantable infusion pumps for use with certain drugs that have precise treatment regimens. Over-dosing or under-dosing might be precluded by way of dosing definitions programmed into secure data storage locations.
- In yet another embodiment, underdosage by the patient could be avoided if the pump is programmed to a minimum dosage or by warning the patient. The warning could be an audio alarm from the pump or an indicator on the patient's controller to which the patient could respond by increasing the dosage.
- The same underdosage alarm could be implemented to alert the patient of a requested overdosage, thereby alerting the patient when a dosage request amounts to an overdosage not allowed by the pump.
-
FIG. 1 discloses a simplified block diagram of an implantable, software controlled infusion pump providing software dosage limits. -
FIG. 2 shows a full system implementation of a pump including, the pump, a catheter, two external controllers, one patient use and one medical person use. -
FIG. 3 shows a diagrammatic view illustrating a patient controller and a physician programmer and their communication with an implantable drug pump. -
FIG. 4 illustrates a method of decreasing drug use in accordance with an embodiment of the invention. -
FIG. 5 illustrates a method of preventing drug underdosage in accordance with an embodiment of the invention. -
FIG. 6 illustrates a method of reducing the number of episodes requiring dose activations in accordance with an embodiment of the invention. -
FIG. 7 illustrates a method of preventing a drug overdose in accordance with an embodiment of the invention. -
FIG. 1 shows a simplified block diagram of the functional elements of an implantable and programmabledrug infusion pump 100 having re-programmable (i.e. software-specified) dosage limits. The functional elements of theinfusion pump 100 shown inFIG. 1 are small, such that the pump can be readily implanted into the abdomen of a patient for purposes of controlling chronic diseases, such as diabetes. An implanted infusion pump might also be used for acute treatment regimens, e.g. to administer chemotherapy drugs or morphine to treat cancer or treat pain respectively. - Referring to
FIG. 1 , areservoir 102 contains some appropriate volume of drug to be administered to the patient by apump 104, preferably a precision positive displacement pump drawing drug material from thereservoir 102. WhileFIG. 1 shows only a single reservoir and a single pump, the invention disclosed herein is readily adapted for use with multiple reservoirs for administering several different drugs or for increasing the volume of a single drug that might be implanted into the patient. Multiple pumps might be also used with multiple reservoirs to administering different drugs at different rates and times. Multiple pumps might be used with a single reservoir for increased reliability. - The
pump 104 is operatively coupled to and responsive to electrical signals delivered to it from acontrol unit 106. Electrical signals from thecontrol unit 106 would, for example, start and stop thepump 104 and including its delivery rate so as to modulate the delivery of drugs from thereservoir 102 to the patient. The control circuitry within thecontrol unit 106 would typically include appropriate electronic drive circuits, the essential function of which is to couple acentral processor 108 to thepump 104 through appropriate interface circuitry well know to those skilled in the art. Alternate embodiments of the invention would of course include implementing any required pump/CPU interface directly into the microprocessor, or selecting and/or designing thepump 104 to eliminate the need for an interface between it and the low power circuits of the microprocessor. Many commercial grade microprocessors include a plethora of ancillary circuitry on a single substrate including analog-to-digital converters, digital-to-analog converters, counters, timers, clocks and so forth. - The
central processor unit 108 controls the amount of drug treatment administered to the patient according to the therapy program instructions stored in aprogram memory 110. The program memory, which could be resident on the same semiconductor substrate as the CPU, typically requires the ability to temporarily store and retrieve data.Random access memory 112 shown inFIG. 1 and well known to those skilled in the art, is available for use by the program executed by theCPU 108. - Those skilled in the art will recognize that while the program executed by the
CPU 108 might be most economically implement in read-only-memory (ROM) structure equivalent to the ROM could include electrically programmable read only memory (EPROM) 114 as well as electrically erasable programmable read-only memory (EEPROM) 116. Both of these alternate structures are capable of retaining executable instructions required by thecentral processing unit 108 to operate and control thepump 100. - The
EPROM 114 and theEEPROM 116 are re-programmable semi-conductor memories as those skilled in the art will recognize.EEPROM 116 is particularly useful in the invention as it readily lends itself as a repository for drug therapy dosage characteristics and is safer than RAM (random access memory) because RAM is volatile and susceptible to errors caused by power source interruption. EEPROM retains data for long periods of time yet is readily re-programmed by the CPU. Many commercially available microprocessors include addressable EEPROM directly on the substrate comprising the CPU further simplifying the implementation of a software-limited dosage implantable drug infusion device.FIG. 2 shows the pump system embodiment including adrug infusion pump 200 and adrug infusion catheter 204, suitable to deliver drugs to a distal sight in the body. Two external controllers are shown, one forpatient use 210 and one formedical person use 220. Thepump 200 with theconnected catheter 204 is implanted in the patient'sbody 216 under theskin 214. For remote programming purposes,RF energy 212 flows bi-directionally between thepump 200 and the patient useexternal controller 210. Similarly, the health care provider uses anexternal controller 220 to independently program the implanted pump to the desire infusion parameters as is commonly done in the art. The manufacturer of thecontroller 220 sets the range ofcontroller 220. A piezoelectric transducer or othersuitable audio enunciator 202 on the pump body or otherwise electrically coupled to the pump and its internal controller might be used to provide an audible alarm to the patient in the case of under or overdosing. - A health care provider programs the
implantable infusion pump 100 using aremote programming device 210, such as the programming device disclosed in U.S. Pat. No. 5,443,486 and U.S. Pat. No. 4,676,248, “Circuit for Controlling a Receiver in an Implanted Device” by Berntson. The program executed by theCPU 108 regularly scans the RF link (embodied by theprogramming control 120 and the uplink telemetry 122) for commands. Alternate embodiments would of course include RF communication link circuits that assert an interrupt control line on so-equipped processors. At least one command recognizable by theCPU 108 is a patient-initiated request to thepump 100 to administer a bolus of drug from thereservoir 102. Such a request would be sent to thepump 100 by the patient being provided with a transponder specifically designed to transmit a bolus-request command. The functionality of the patient-operateddevice 210 is limited and incapable of altering key data programmed by a health care provider. - Both the health-care provided instructions and the patient requested doses are delivered to the
CPU 108 through an input port on the CPU. Such an input port of theCPU 108 would include a memory mapped input/output device or other parallel or appropriate buffered serial input port, all of which are commonly found on many commercially available micro controllers. - In the course of programming, the infusion pump, the health care professional can specify a dose infusion characteristic parameter to be stored into one or more of the
memory locations memory device 109 depictingFIG. 1 . The dose infusion characteristic stored in memory may be one or more bytes of data (recognizable by the program instructions) to limit the amount, frequency, or other characteristic(s) of a dose of the drug to be administered to the patient by thepump 100. The dose infusion characteristics could also prescribe dosage minimum dosage amounts as well. - For example, the dose infusion characteristic stored in one of the memory locations (124, 126, 128) in
FIG. 1 could be used by the program stored inROM 110 to limit the number of drug bolus deliveries that a patient may initiate in a twenty-four hour period. Alternatively, the drug dose infusion characteristic might control the volume of drug to be delivered upon the request of the patient over a given period of time. The bolus frequency, bolus dosage size per unit time, bolus size, or other dose information might also be stored. - Similarly, a drug dose infusion characteristic might be programmed into one of the
memory locations ROM 110 orEPROM - In an alternate embodiment, the
CPU 108 might scan or poll sensors (not shown) providing data on the efficacy of the treatment. Alternate dosages might be indicated by input from one or more sensors. Dose limits would still provide a means by which maximum or minimum treatments would not be exceeded. - Those skilled in the art will recognize that the
controller 108 is preferably a programmable microcontroller or microprocessor. Such devices are well known in the electronics art and many include read-only memory, random access memory, EPROM and EEPROM on board the device. Such devices also routinely include a/d converters, d/a converters, counters, timers, and other circuits usable in a real time control application including an implantable infusion pump. - Altering embodiments might include combinational as well as sequential logic although those skilled in the art will recognize the inherent advantages of using a microprocessor or micro controller. Still other embodiments would contemplate using analog devices, such as an analog computer to control the
pump 104 in response to bodily conditions. - Program instructions for the
controller 108 are stored an appropriate memory device. Program instructions might also be stored in ROM, RAM, EPROM or EEPROM as set forth above. Infusion limits or dose characteristics are preferably stored in a programmable memory location, such as EPROM or EEPROM because of their ability to retain data over long periods of time, even if power is lost. In the case of random access memory (RAM) power may have to be continuously applied to the memory device and any ancillary circuitry to avoid data loss. - In operation, a health care professional would preferably download programming and/or data into the
memory device 109 through theRF interlink circuitry FIG. 1 , these programming instructions and/or data have passed through thecentral processing unit 108. Depiction of this data path inFIG. 1 should not be construed as limiting. Sufficient intelligence might be built into the RF link circuitry to directly load random access memory orother memory devices 109 directly through the programming link. -
FIG. 3 represents an alternative embodiment to the configuration of thepatient controller 310 and thephysician programmer 320. In this embodiment, thepatient controller 310 contains atherapy program 306 for possible drug infusion rate adjustments. Thepatient controller 310 also contains amicroprocessor 318 andmemory 326 that would store treatment information such as base rate drug flows, the maximum and minimum daily allowable doses, patient activation requests, and drug delivery monitoring data. The health care provider would use thephysician programmer 320 to specify the drug infusion characteristics that may include the maximum and minimum daily allowance dosages, 24 hour rolling average rate limits, nominal dosage rates, and a minimum time interval between bolus requests. In particular, the health care provider may program two or more different base infusion rates that would be acceptable in reaching the daily dosages. The nominal dosage rates would be the default rates and a patient could then select a different base rate using thepatient controller 310 depending on the needed amount of therapy at any given time of the day. Thepatient controller 310 through thetherapy program 306 would only allow a base rate change to those rates already approved by the health care professional. - Optionally, the
patient controller 310 may also contain a notification mechanism to provide feedback to the patient. For example and without limitation, thepatient controller 310 may contain anaudio speaker 302 and aLCD display 304 to provide the patient with alarm, status and task information. The alarm information would be generated from the changes in the patient controller therapy program output. A brief overview of some of the steps that the therapy program would perform in determining whether the proper amount of drugs are being administered are shown inFIGS. 4, 5 , 6, and 7. These steps generally track drug infusion characteristics and allows the patient to adjust the therapy to provide a more efficient and effective drug treatment. -
FIG. 4 illustrates the steps that may be performed by the therapy program to determine whether the amount of drug being administered should be decreased. This may occur, for example, when the patient is not administering any additional bolus of drug, thereby suggesting that the base rate could possibly be reduced. Instep 402, the therapy program determines whether the patient has requested a dose of medication in a specified period of time. This dose request by the patient could be either a bolus dose or an increase in the base rate. The specified period of time would depend on the type of drug being administered and may be, for example, based one or more days or one or more hours. If the patient has requested dose activation within the specified period of time, then the program does not make any changes, atstep 404. If, on the other hand, the patient has not requested a dose indication within the specified time, atstep 406, then the drug therapy could be reduced. Either the patient would be prompted, by the notification mechanism, to use the patient controller to select the next lowest base rate to reduce drug usage, or the therapy program could activate the smallest programmed dose when the patient makes an activation request. These steps ensure that a patient is not being over medicated by a base infusion rate flow that is larger than the patient's current medication requirements. -
FIG. 5 illustrates the steps that may be performed by the therapy program to prevent drug underdosage. Instep 502, the therapy program determines whether a patient is nearing an underdosage condition. The program tracks the patient drug therapy and therefore, knows the actual total dosage being delivered to the patient. The actual total dosage delivered to the patient is the combination of the base rate and the number of bolus activations over the specified time period. The program also knows the minimum allowed dosage that is desired for a particular drug. The program compares the actual dosage and the minimum allowed dosage. If the actual dosage is within a predetermined percentage of the minimum allowed dosage then the patient is nearing an underdosage condition. This tracking of the total dosage allows flexibility in the administering of the drug therapy. For example, the physician may prescribe a base rate over the course of a period of time below the minimum dosage with the knowledge that the patient will be administering a number of bolus dosages during that period of time. The combination of the base rate and the bolus dosage activations over the course of that time period would together reach the minimum allowed dosage. If the patient is not nearing an underdosage condition then the therapy program does not make any changes atstep 504. If, however, the therapy program determines that a patient is nearing an underdosage condition then the therapy program may prompt the patient, through the client notification system, to use the patient controller to either activate a bolus dose of medication or to use the next highest base rate as depicted instep 506. This reminds the patient to make sure that they administer their bolus dosages. This type of notification is important, as preventing underdosing is important in many drug therapy plans. For example, in the case of Baclofen for spasticity, drug withdrawal has serious side effects and is a major concern. -
FIG. 6 illustrates the steps that may be performed by the therapy program to determine whether the patient has requested too many bolus activations over a specified period of time. Instep 602, the therapy program determines whether the patient has requested more bolus activations than allowed by the health care provider. Because the program tracks the patient drug therapy, the program knows the number of bolus activations and bolus activation requests over a specified time period. If the number of bolus activations is below the allowable amount, then the therapy program continues in its normal fashion atstep 604. If, however, the patient has had more than the allowed number of drug bolus activations then the patient would be prompted by the notification mechanism to use the patient controller to select a higher base rate in an attempt to reduce the amount of future bolus activation requests. -
FIG. 7 illustrates the steps that may be performed by the therapy program to prevent a drug overdosage. In step 702, it is determined whether the patient is currently utilizing the highest base rate allowed by the health care provider. Because the program tracks the patient drug therapy, the program knows the current base rate and the highest base rate programmed by the physician. If the patient is not at the highest base rate then the therapy program continues as normal at step 704. However, if the base rate is at the highest allowable setting then the therapy program determines whether the patient is nearing his or her maximum daily dose atstep 706. If the patient is not nearing his or her maximum daily dose then the therapy program stops the inquiry and continues as normal atstep 708. However, if the patient is nearing the maximum daily dose then the therapy program could deny further activation requests, activate the smallest programmed dose when an activation request is made by the patient or prompt the patient to select the next lowest base rate. - By use of the invention disclosed herein, the likelihood of overdosing a patient with a drug from an implanted and therefore an inaccessible diffusion pump is reduced. Software based limits programmed into a microcomputer increased the flexibility of the implanted pump for a wider range of therapies compared to prior art, hard-wired devices. The software-based limits add an increased level of safety not found in prior art implantable drug infusion pumps devices.
- The description of the apparatus of this invention is not intended to be limiting but is merely illustrative of the preferred embodiment of this invention. Those of ordinary skill in the art will recognize that modifications can be made without departure from the true spirit and scope of the invention.
- The true spirit and scope of the inventions of this specification are best defined by the appended claims, to be interpreted in light of the foregoing specification. Other apparatus which incorporate modifications or changes to that which has been described herein are equally included within the scope of the following claims and equivalents thereof. Therefore, to particularly point out and distinctly claim the subject matter regarded as the invention, the following claims conclude this specification.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/921,015 US7776031B2 (en) | 1999-04-30 | 2004-08-18 | Method and apparatus to control drug therapy dosages in an implantable pump |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30330799A | 1999-04-30 | 1999-04-30 | |
US09/804,136 US6796956B2 (en) | 1999-04-30 | 2001-03-12 | Method and apparatus to control drug therapy dosages in an implantable pump |
US10/921,015 US7776031B2 (en) | 1999-04-30 | 2004-08-18 | Method and apparatus to control drug therapy dosages in an implantable pump |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/804,136 Division US6796956B2 (en) | 1999-04-30 | 2001-03-12 | Method and apparatus to control drug therapy dosages in an implantable pump |
Publications (2)
Publication Number | Publication Date |
---|---|
US20050020996A1 true US20050020996A1 (en) | 2005-01-27 |
US7776031B2 US7776031B2 (en) | 2010-08-17 |
Family
ID=25188272
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/804,136 Expired - Lifetime US6796956B2 (en) | 1999-04-30 | 2001-03-12 | Method and apparatus to control drug therapy dosages in an implantable pump |
US10/921,015 Expired - Fee Related US7776031B2 (en) | 1999-04-30 | 2004-08-18 | Method and apparatus to control drug therapy dosages in an implantable pump |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/804,136 Expired - Lifetime US6796956B2 (en) | 1999-04-30 | 2001-03-12 | Method and apparatus to control drug therapy dosages in an implantable pump |
Country Status (3)
Country | Link |
---|---|
US (2) | US6796956B2 (en) |
EP (1) | EP1370312A1 (en) |
WO (1) | WO2002072178A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1801718A1 (en) * | 2005-12-21 | 2007-06-27 | F. Hoffmann-La Roche AG | Method for operating a computer controlled dosing device for liquid medicine in situations of travel time shift |
US20110152769A1 (en) * | 2009-12-23 | 2011-06-23 | Roche Diagnostics Operations, Inc. | Methods and systems for adjusting an insulin delivery profile of an insulin pump |
US20130204433A1 (en) * | 2000-05-18 | 2013-08-08 | Carefusion 303, Inc. | Patient-specific medication management system |
US20140276531A1 (en) * | 2013-03-13 | 2014-09-18 | Tandem Diabetes Care, Inc. | System and method for maximum insulin pump bolus override |
US9307907B2 (en) | 2004-08-25 | 2016-04-12 | CareFusion 303,Inc. | System and method for dynamically adjusting patient therapy |
US9427520B2 (en) | 2005-02-11 | 2016-08-30 | Carefusion 303, Inc. | Management of pending medication orders |
US9522261B2 (en) | 2010-01-22 | 2016-12-20 | Hugh E Montgomery | Method and apparatus for providing hydration fluid |
US9600633B2 (en) | 2000-05-18 | 2017-03-21 | Carefusion 303, Inc. | Distributed remote asset and medication management drug delivery system |
US20170112434A1 (en) * | 2015-10-22 | 2017-04-27 | Welch Allyn, Inc. | Method and apparatus for delivering a substance to an individual |
US9741001B2 (en) | 2000-05-18 | 2017-08-22 | Carefusion 303, Inc. | Predictive medication safety |
US10029047B2 (en) | 2013-03-13 | 2018-07-24 | Carefusion 303, Inc. | Patient-specific medication management system |
US10062457B2 (en) | 2012-07-26 | 2018-08-28 | Carefusion 303, Inc. | Predictive notifications for adverse patient events |
US10353856B2 (en) | 2011-03-17 | 2019-07-16 | Carefusion 303, Inc. | Scalable communication system |
US10430554B2 (en) | 2013-05-23 | 2019-10-01 | Carefusion 303, Inc. | Medication preparation queue |
CN111729161A (en) * | 2012-11-28 | 2020-10-02 | 方特慕控股第一私人有限公司 | Methods and devices for compound delivery |
US10867265B2 (en) | 2013-03-13 | 2020-12-15 | Carefusion 303, Inc. | Predictive medication safety |
US11087873B2 (en) | 2000-05-18 | 2021-08-10 | Carefusion 303, Inc. | Context-aware healthcare notification system |
US11182728B2 (en) | 2013-01-30 | 2021-11-23 | Carefusion 303, Inc. | Medication workflow management |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8241270B2 (en) * | 1999-04-30 | 2012-08-14 | Medtronic, Inc. | Drug infusion system and method adapted to start during programming cycle |
US6796956B2 (en) | 1999-04-30 | 2004-09-28 | Medtronic, Inc. | Method and apparatus to control drug therapy dosages in an implantable pump |
US6519569B1 (en) * | 1999-12-01 | 2003-02-11 | B. Braun Medical, Inc. | Security infusion pump with bar code reader |
US7645258B2 (en) | 1999-12-01 | 2010-01-12 | B. Braun Medical, Inc. | Patient medication IV delivery pump with wireless communication to a hospital information management system |
US6974437B2 (en) * | 2000-01-21 | 2005-12-13 | Medtronic Minimed, Inc. | Microprocessor controlled ambulatory medical apparatus with hand held communication device |
SE516707C2 (en) * | 2000-05-30 | 2002-02-19 | Volvo Lastvagnar Ab | Power units for motor vehicles |
US7072725B2 (en) * | 2001-03-26 | 2006-07-04 | Medtronic, Inc. | Implantable therapeutic substance infusion device configuration system |
US7083593B2 (en) * | 2001-04-18 | 2006-08-01 | Advanced Bionics Corporation | Programmable implantable pump with accessory reservoirs and multiple independent lumen catheter |
US8152789B2 (en) * | 2001-10-23 | 2012-04-10 | Medtronic Minimed, Inc. | System and method for providing closed loop infusion formulation delivery |
US6827702B2 (en) * | 2001-09-07 | 2004-12-07 | Medtronic Minimed, Inc. | Safety limits for closed-loop infusion pump control |
MXPA04004246A (en) * | 2001-11-01 | 2004-09-10 | Scott Lab Inc | User interface for sedation and analgesia delivery systems and methods. |
US10173008B2 (en) | 2002-01-29 | 2019-01-08 | Baxter International Inc. | System and method for communicating with a dialysis machine through a network |
US8775196B2 (en) | 2002-01-29 | 2014-07-08 | Baxter International Inc. | System and method for notification and escalation of medical data |
FI116507B (en) * | 2002-02-27 | 2005-12-15 | Aniwell Oy | Animal monitoring system |
US8128616B2 (en) * | 2002-03-27 | 2012-03-06 | Medtronic, Inc. | System, method and implantable device for delivery of therapeutic substance |
US20030204274A1 (en) * | 2002-04-26 | 2003-10-30 | Medtronic, Inc. | Patient controlled activation with implantable drug delivery devices |
US8234128B2 (en) | 2002-04-30 | 2012-07-31 | Baxter International, Inc. | System and method for verifying medical device operational parameters |
US7967812B2 (en) * | 2002-10-22 | 2011-06-28 | Medtronic, Inc. | Drug infusion system programmable in flex mode |
US20040077996A1 (en) * | 2002-10-22 | 2004-04-22 | Jasperson Keith E. | Drug infusion system with multiple medications |
US20040098065A1 (en) * | 2002-11-19 | 2004-05-20 | Alliance Health Products, Llc | Transcutaneous nerve and muscle stimulator and method of using the same |
CA2523267C (en) | 2003-04-23 | 2013-09-03 | Biovalve Technologies, Inc. | Hydraulically actuated pump for long duration medicament administration |
US7263406B2 (en) | 2003-10-02 | 2007-08-28 | Medtronic, Inc. | Medical device programmer with selective disablement of display during telemetry |
US8065161B2 (en) | 2003-11-13 | 2011-11-22 | Hospira, Inc. | System for maintaining drug information and communicating with medication delivery devices |
US9123077B2 (en) | 2003-10-07 | 2015-09-01 | Hospira, Inc. | Medication management system |
US7232435B2 (en) * | 2004-02-06 | 2007-06-19 | Medtronic, Inc. | Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure |
US7846094B2 (en) * | 2004-03-17 | 2010-12-07 | Miller Landon C G | System and method for neurological injury detection, classification and subsequent injury amelioration |
US8282625B2 (en) * | 2004-04-30 | 2012-10-09 | Medtronic, Inc. | Implantable medical device with time for therapeutic output replenishment determination and method therefore |
US7927313B2 (en) | 2004-05-27 | 2011-04-19 | Baxter International Inc. | Medical device configuration based on recognition of identification information |
US8961461B2 (en) | 2004-05-27 | 2015-02-24 | Baxter International Inc. | Multi-state alarm system for a medical pump |
WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
US8034030B2 (en) * | 2005-05-25 | 2011-10-11 | Palyon Medical (Bvi) Limited | Multi-reservoir implantable pump with variable flow rate capabilities |
DE602006011000D1 (en) | 2005-05-26 | 2010-01-21 | Infusion Systems Llc | IMPLANTABLE INFUSION DEVICE WITH SEVERAL CONTROLLABLE LIQUID OUTPUTS |
WO2006125692A1 (en) * | 2005-05-26 | 2006-11-30 | Novo Nordisk A/S | A dosing operation in a medical device |
US9089713B2 (en) * | 2005-08-31 | 2015-07-28 | Michael Sasha John | Methods and systems for semi-automatic adjustment of medical monitoring and treatment |
US7817030B2 (en) | 2005-11-09 | 2010-10-19 | Invention Science Fund 1, Llc | Remote controller for in situ reaction device |
US8273071B2 (en) | 2006-01-18 | 2012-09-25 | The Invention Science Fund I, Llc | Remote controller for substance delivery system |
US8936590B2 (en) | 2005-11-09 | 2015-01-20 | The Invention Science Fund I, Llc | Acoustically controlled reaction device |
US8083710B2 (en) | 2006-03-09 | 2011-12-27 | The Invention Science Fund I, Llc | Acoustically controlled substance delivery device |
US8998886B2 (en) | 2005-12-13 | 2015-04-07 | The Invention Science Fund I, Llc | Remote control of osmotic pump device |
US7942867B2 (en) | 2005-11-09 | 2011-05-17 | The Invention Science Fund I, Llc | Remotely controlled substance delivery device |
US8992511B2 (en) | 2005-11-09 | 2015-03-31 | The Invention Science Fund I, Llc | Acoustically controlled substance delivery device |
US7708730B2 (en) | 2006-01-30 | 2010-05-04 | Palyon Medical (Bvi) Limited | Template system for multi-reservoir implantable pump |
CN103239773B (en) | 2006-03-30 | 2015-08-26 | 瓦莱里塔斯公司 | Multi-cartridge fluid delivery device |
US20070260174A1 (en) * | 2006-05-05 | 2007-11-08 | Searete Llc | Detecting a failure to maintain a regimen |
JP5241714B2 (en) | 2006-07-07 | 2013-07-17 | プロテウス デジタル ヘルス, インコーポレイテッド | Smart parenteral delivery system |
EP2092470A2 (en) | 2006-10-16 | 2009-08-26 | Hospira, Inc. | System and method for comparing and utilizing activity information and configuration information from mulitple device management systems |
US8229562B2 (en) * | 2006-10-25 | 2012-07-24 | Codman NeuroSciences Sárl | Universal external control device for use by multiple conditional access users with varying access to functionality of an implantable medical device |
US9135810B2 (en) * | 2006-11-28 | 2015-09-15 | Medallion Therapeutics, Inc. | Method, apparatus and system for assigning remote control device to ambulatory medical device |
US8683381B2 (en) * | 2007-08-09 | 2014-03-25 | Alfred E. Mann Foundation For Scientific Research | Drug delivery safety system |
EP2211974A4 (en) | 2007-10-25 | 2013-02-27 | Proteus Digital Health Inc | Fluid transfer port information system |
US8419638B2 (en) | 2007-11-19 | 2013-04-16 | Proteus Digital Health, Inc. | Body-associated fluid transport structure evaluation devices |
EP2227769A2 (en) * | 2007-11-28 | 2010-09-15 | Medtronic, Inc. | Method and apparatus for multi-input stepwise infusion prescription with sensor data |
US8160695B2 (en) | 2007-12-05 | 2012-04-17 | The Invention Science Fund I, Llc | System for chemical modulation of neural activity |
US8165668B2 (en) | 2007-12-05 | 2012-04-24 | The Invention Science Fund I, Llc | Method for magnetic modulation of neural conduction |
US8165669B2 (en) | 2007-12-05 | 2012-04-24 | The Invention Science Fund I, Llc | System for magnetic modulation of neural conduction |
US8233976B2 (en) | 2007-12-05 | 2012-07-31 | The Invention Science Fund I, Llc | System for transdermal chemical modulation of neural activity |
US8180446B2 (en) | 2007-12-05 | 2012-05-15 | The Invention Science Fund I, Llc | Method and system for cyclical neural modulation based on activity state |
US8195287B2 (en) | 2007-12-05 | 2012-06-05 | The Invention Science Fund I, Llc | Method for electrical modulation of neural conduction |
US8170660B2 (en) | 2007-12-05 | 2012-05-01 | The Invention Science Fund I, Llc | System for thermal modulation of neural activity |
US8170658B2 (en) | 2007-12-05 | 2012-05-01 | The Invention Science Fund I, Llc | System for electrical modulation of neural conduction |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
US10089443B2 (en) | 2012-05-15 | 2018-10-02 | Baxter International Inc. | Home medical device systems and methods for therapy prescription and tracking, servicing and inventory |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
EP2334234A4 (en) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | Solute concentration measurement device and related methods |
US8554579B2 (en) | 2008-10-13 | 2013-10-08 | Fht, Inc. | Management, reporting and benchmarking of medication preparation |
US8246565B2 (en) | 2009-02-25 | 2012-08-21 | The Invention Science Fund I, Llc | Device for passively removing a target component from blood or lymph of a vertebrate subject |
US8317737B2 (en) * | 2009-02-25 | 2012-11-27 | The Invention Science Fund I, Llc | Device for actively removing a target component from blood or lymph of a vertebrate subject |
US8271106B2 (en) | 2009-04-17 | 2012-09-18 | Hospira, Inc. | System and method for configuring a rule set for medical event management and responses |
WO2011014704A2 (en) | 2009-07-30 | 2011-02-03 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US8332020B2 (en) | 2010-02-01 | 2012-12-11 | Proteus Digital Health, Inc. | Two-wrist data gathering system |
AU2011210648B2 (en) | 2010-02-01 | 2014-10-16 | Otsuka Pharmaceutical Co., Ltd. | Data gathering system |
US9953138B2 (en) | 2010-06-29 | 2018-04-24 | Codman Neuro Sciences Sarl | Drug component admixture library for a drug infusion delivery system |
EP2404633A1 (en) * | 2010-07-07 | 2012-01-11 | Sanofi-Aventis Deutschland GmbH | Drug delivery device and system of drug delivery devices |
US9211378B2 (en) | 2010-10-22 | 2015-12-15 | Cequr Sa | Methods and systems for dosing a medicament |
US10719584B2 (en) * | 2011-02-10 | 2020-07-21 | Medtronic, Inc. | Medical fluid delivery device programming |
US9940440B2 (en) | 2011-04-28 | 2018-04-10 | Medtronic, Inc. | Detecting and responding to software and hardware anomalies in a fluid delivery system |
ES2959510T3 (en) | 2011-10-21 | 2024-02-26 | Icu Medical Inc | Medical device update system |
US8591456B2 (en) | 2011-12-28 | 2013-11-26 | Palyon Medical (Bvi) Limited | Multiple reservoir programmable pump |
US10286148B2 (en) * | 2012-01-23 | 2019-05-14 | Fenwal, Inc. | Using physiological data in a medical device |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
US9238100B2 (en) | 2012-06-07 | 2016-01-19 | Tandem Diabetes Care, Inc. | Device and method for training users of ambulatory medical devices |
SG11201503190RA (en) | 2012-10-26 | 2015-05-28 | Baxter Corp Englewood | Improved image acquisition for medical dose preparation system |
EP2911641B1 (en) | 2012-10-26 | 2018-10-17 | Baxter Corporation Englewood | Improved work station for medical dose preparation system |
AU2014225658B2 (en) | 2013-03-06 | 2018-05-31 | Icu Medical, Inc. | Medical device communication method |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
JP6621748B2 (en) | 2013-08-30 | 2019-12-18 | アイシーユー・メディカル・インコーポレーテッド | System and method for monitoring and managing a remote infusion regimen |
US9662436B2 (en) | 2013-09-20 | 2017-05-30 | Icu Medical, Inc. | Fail-safe drug infusion therapy system |
US10311972B2 (en) | 2013-11-11 | 2019-06-04 | Icu Medical, Inc. | Medical device system performance index |
WO2015077320A1 (en) | 2013-11-19 | 2015-05-28 | Hospira, Inc. | Infusion pump automation system and method |
EP2910765B1 (en) | 2014-02-21 | 2017-10-25 | Rolls-Royce Corporation | Single phase micro/mini channel heat exchangers for gas turbine intercooling and corresponding method |
JP6853669B2 (en) | 2014-04-30 | 2021-03-31 | アイシーユー・メディカル・インコーポレーテッド | Patient treatment system with conditional alert forwarding |
US9724470B2 (en) | 2014-06-16 | 2017-08-08 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
US9717845B2 (en) * | 2014-08-19 | 2017-08-01 | Medtronic Minimed, Inc. | Geofencing for medical devices |
US9539383B2 (en) | 2014-09-15 | 2017-01-10 | Hospira, Inc. | System and method that matches delayed infusion auto-programs with manually entered infusion programs and analyzes differences therein |
EP3195160B1 (en) * | 2014-09-16 | 2020-06-03 | Medituner AB | Computer controlled dosage system |
US11107574B2 (en) | 2014-09-30 | 2021-08-31 | Baxter Corporation Englewood | Management of medication preparation with formulary management |
WO2016090091A1 (en) | 2014-12-05 | 2016-06-09 | Baxter Corporation Englewood | Dose preparation data analytics |
EP3265989A4 (en) | 2015-03-03 | 2018-10-24 | Baxter Corporation Englewood | Pharmacy workflow management with integrated alerts |
WO2016189417A1 (en) | 2015-05-26 | 2016-12-01 | Hospira, Inc. | Infusion pump system and method with multiple drug library editor source capability |
CA2985719C (en) | 2015-06-25 | 2024-03-26 | Gambro Lundia Ab | Medical device system and method having a distributed database |
US10293101B2 (en) | 2016-01-14 | 2019-05-21 | Bigfoot Biomedical, Inc. | Diabetes management system |
EP3484541A4 (en) | 2016-07-14 | 2020-03-25 | ICU Medical, Inc. | Multi-communication path selection and security system for a medical device |
WO2018114346A1 (en) | 2016-12-21 | 2018-06-28 | Gambro Lundia Ab | Medical device system including information technology infrastructure having secure cluster domain supporting external domain |
US10950339B2 (en) | 2018-07-17 | 2021-03-16 | Icu Medical, Inc. | Converting pump messages in new pump protocol to standardized dataset messages |
US11139058B2 (en) | 2018-07-17 | 2021-10-05 | Icu Medical, Inc. | Reducing file transfer between cloud environment and infusion pumps |
EP3824383B1 (en) | 2018-07-17 | 2023-10-11 | ICU Medical, Inc. | Systems and methods for facilitating clinical messaging in a network environment |
NZ771914A (en) | 2018-07-17 | 2023-04-28 | Icu Medical Inc | Updating infusion pump drug libraries and operational software in a networked environment |
AU2019309766A1 (en) | 2018-07-26 | 2021-03-18 | Icu Medical, Inc. | Drug library management system |
US10692595B2 (en) | 2018-07-26 | 2020-06-23 | Icu Medical, Inc. | Drug library dynamic version management |
US11383093B1 (en) | 2019-12-06 | 2022-07-12 | Hoseon LEE | Radiation release capsule |
CN112712872A (en) * | 2020-12-29 | 2021-04-27 | 查维祎 | Automatic injection device and using method thereof |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4676248A (en) * | 1982-04-30 | 1987-06-30 | Medtronic, Inc. | Circuit for controlling a receiver in an implanted device |
US4714462A (en) * | 1986-02-03 | 1987-12-22 | Intermedics Infusaid, Inc. | Positive pressure programmable infusion pump |
US4731051A (en) * | 1979-04-27 | 1988-03-15 | The Johns Hopkins University | Programmable control means for providing safe and controlled medication infusion |
US5069668A (en) * | 1990-07-12 | 1991-12-03 | Boydman Scott A | Patient controlled analgesia system |
US5443486A (en) * | 1994-09-26 | 1995-08-22 | Medtronic, Inc. | Method and apparatus to limit control of parameters of electrical tissue stimulators |
US5582593A (en) * | 1994-07-21 | 1996-12-10 | Hultman; Barry W. | Ambulatory medication delivery system |
US5832932A (en) * | 1996-04-30 | 1998-11-10 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US6165155A (en) * | 1997-02-07 | 2000-12-26 | Sarcos, Lc | Multipathway electronically-controlled drug delivery system |
US6361522B1 (en) * | 1999-10-21 | 2002-03-26 | Cardiac Pacemakers, Inc. | Drug delivery system for implantable cardiac device |
US6427088B1 (en) * | 2000-01-21 | 2002-07-30 | Medtronic Minimed, Inc. | Ambulatory medical apparatus and method using telemetry system with predefined reception listening periods |
US6554822B1 (en) * | 1999-04-30 | 2003-04-29 | University Of Southern California | Microbolus infusion pump |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6796956B2 (en) | 1999-04-30 | 2004-09-28 | Medtronic, Inc. | Method and apparatus to control drug therapy dosages in an implantable pump |
FR2792839A1 (en) | 1999-04-30 | 2000-11-03 | Medtronic Inc | SYSTEM AND METHOD FOR LIMITING THE DOSAGE OF A MEDICAMENT IN AN IMPLANTABLE PUMP |
WO2001052935A1 (en) | 2000-01-21 | 2001-07-26 | Medical Research Group, Inc. | Ambulatory medical apparatus and method having telemetry modifiable control software |
ATE552869T1 (en) | 2000-01-21 | 2012-04-15 | Medtronic Minimed Inc | MICROPROCESSOR-CONTROLLED, AMBULATORY MEDICAL DEVICE WITH HAND-HOLD COMMUNICATION DEVICE |
-
2001
- 2001-03-12 US US09/804,136 patent/US6796956B2/en not_active Expired - Lifetime
-
2002
- 2002-03-01 WO PCT/US2002/006720 patent/WO2002072178A1/en not_active Application Discontinuation
- 2002-03-01 EP EP02750569A patent/EP1370312A1/en not_active Withdrawn
-
2004
- 2004-08-18 US US10/921,015 patent/US7776031B2/en not_active Expired - Fee Related
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4731051A (en) * | 1979-04-27 | 1988-03-15 | The Johns Hopkins University | Programmable control means for providing safe and controlled medication infusion |
US4676248A (en) * | 1982-04-30 | 1987-06-30 | Medtronic, Inc. | Circuit for controlling a receiver in an implanted device |
US4714462A (en) * | 1986-02-03 | 1987-12-22 | Intermedics Infusaid, Inc. | Positive pressure programmable infusion pump |
US5069668A (en) * | 1990-07-12 | 1991-12-03 | Boydman Scott A | Patient controlled analgesia system |
US5582593A (en) * | 1994-07-21 | 1996-12-10 | Hultman; Barry W. | Ambulatory medication delivery system |
US5443486A (en) * | 1994-09-26 | 1995-08-22 | Medtronic, Inc. | Method and apparatus to limit control of parameters of electrical tissue stimulators |
US5832932A (en) * | 1996-04-30 | 1998-11-10 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US6165155A (en) * | 1997-02-07 | 2000-12-26 | Sarcos, Lc | Multipathway electronically-controlled drug delivery system |
US6554822B1 (en) * | 1999-04-30 | 2003-04-29 | University Of Southern California | Microbolus infusion pump |
US6361522B1 (en) * | 1999-10-21 | 2002-03-26 | Cardiac Pacemakers, Inc. | Drug delivery system for implantable cardiac device |
US6427088B1 (en) * | 2000-01-21 | 2002-07-30 | Medtronic Minimed, Inc. | Ambulatory medical apparatus and method using telemetry system with predefined reception listening periods |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9600633B2 (en) | 2000-05-18 | 2017-03-21 | Carefusion 303, Inc. | Distributed remote asset and medication management drug delivery system |
US11087873B2 (en) | 2000-05-18 | 2021-08-10 | Carefusion 303, Inc. | Context-aware healthcare notification system |
US10275571B2 (en) | 2000-05-18 | 2019-04-30 | Carefusion 303, Inc. | Distributed remote asset and medication management drug delivery system |
US20130204433A1 (en) * | 2000-05-18 | 2013-08-08 | Carefusion 303, Inc. | Patient-specific medication management system |
US11823791B2 (en) | 2000-05-18 | 2023-11-21 | Carefusion 303, Inc. | Context-aware healthcare notification system |
US9069887B2 (en) * | 2000-05-18 | 2015-06-30 | Carefusion 303, Inc. | Patient-specific medication management system |
US9741001B2 (en) | 2000-05-18 | 2017-08-22 | Carefusion 303, Inc. | Predictive medication safety |
US9307907B2 (en) | 2004-08-25 | 2016-04-12 | CareFusion 303,Inc. | System and method for dynamically adjusting patient therapy |
US10064579B2 (en) | 2004-08-25 | 2018-09-04 | Carefusion 303, Inc. | System and method for dynamically adjusting patient therapy |
US11590281B2 (en) | 2005-02-11 | 2023-02-28 | Carefusion 303, Inc. | Management of pending medication orders |
US10668211B2 (en) | 2005-02-11 | 2020-06-02 | Carefusion 303, Inc. | Management of pending medication orders |
US9981085B2 (en) | 2005-02-11 | 2018-05-29 | Carefusion, 303, Inc. | Management of pending medication orders |
US9427520B2 (en) | 2005-02-11 | 2016-08-30 | Carefusion 303, Inc. | Management of pending medication orders |
EP1801718A1 (en) * | 2005-12-21 | 2007-06-27 | F. Hoffmann-La Roche AG | Method for operating a computer controlled dosing device for liquid medicine in situations of travel time shift |
US8092428B2 (en) | 2009-12-23 | 2012-01-10 | Roche Diagnostics Operations, Inc. | Methods and systems for adjusting an insulin delivery profile of an insulin pump |
US20110152769A1 (en) * | 2009-12-23 | 2011-06-23 | Roche Diagnostics Operations, Inc. | Methods and systems for adjusting an insulin delivery profile of an insulin pump |
US8491566B2 (en) | 2009-12-23 | 2013-07-23 | Roche Diagnostics Operations, Inc. | Methods and systems for adjusting an insulin delivery profile of an insulin pump |
US9522261B2 (en) | 2010-01-22 | 2016-12-20 | Hugh E Montgomery | Method and apparatus for providing hydration fluid |
US11366781B2 (en) | 2011-03-17 | 2022-06-21 | Carefusion 303, Inc. | Scalable communication system |
US10353856B2 (en) | 2011-03-17 | 2019-07-16 | Carefusion 303, Inc. | Scalable communication system |
US11734222B2 (en) | 2011-03-17 | 2023-08-22 | Carefusion 303, Inc. | Scalable communication system |
US10983946B2 (en) | 2011-03-17 | 2021-04-20 | Carefusion 303, Inc. | Scalable communication system |
US10062457B2 (en) | 2012-07-26 | 2018-08-28 | Carefusion 303, Inc. | Predictive notifications for adverse patient events |
CN111729161A (en) * | 2012-11-28 | 2020-10-02 | 方特慕控股第一私人有限公司 | Methods and devices for compound delivery |
US11182728B2 (en) | 2013-01-30 | 2021-11-23 | Carefusion 303, Inc. | Medication workflow management |
US10867265B2 (en) | 2013-03-13 | 2020-12-15 | Carefusion 303, Inc. | Predictive medication safety |
US10937530B2 (en) | 2013-03-13 | 2021-03-02 | Carefusion 303, Inc. | Patient-specific medication management system |
US10029047B2 (en) | 2013-03-13 | 2018-07-24 | Carefusion 303, Inc. | Patient-specific medication management system |
US11484642B2 (en) | 2013-03-13 | 2022-11-01 | Tandem Diabetes Care, Inc. | System and method for maximum insulin pump bolus override |
US9940441B2 (en) * | 2013-03-13 | 2018-04-10 | Tandem Diabetes Care, Inc. | System and method for maximum insulin pump bolus override |
US11615871B2 (en) | 2013-03-13 | 2023-03-28 | Carefusion 303, Inc. | Patient-specific medication management system |
US20140276531A1 (en) * | 2013-03-13 | 2014-09-18 | Tandem Diabetes Care, Inc. | System and method for maximum insulin pump bolus override |
US10430554B2 (en) | 2013-05-23 | 2019-10-01 | Carefusion 303, Inc. | Medication preparation queue |
US10964421B2 (en) * | 2015-10-22 | 2021-03-30 | Welch Allyn, Inc. | Method and apparatus for delivering a substance to an individual |
US20170112434A1 (en) * | 2015-10-22 | 2017-04-27 | Welch Allyn, Inc. | Method and apparatus for delivering a substance to an individual |
Also Published As
Publication number | Publication date |
---|---|
WO2002072178A9 (en) | 2004-04-08 |
EP1370312A1 (en) | 2003-12-17 |
US20010037083A1 (en) | 2001-11-01 |
US7776031B2 (en) | 2010-08-17 |
US6796956B2 (en) | 2004-09-28 |
WO2002072178A1 (en) | 2002-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7776031B2 (en) | Method and apparatus to control drug therapy dosages in an implantable pump | |
US9940440B2 (en) | Detecting and responding to software and hardware anomalies in a fluid delivery system | |
US8612055B2 (en) | System and method for delivering a therapeutic agent according to default infusion schedule | |
US8795260B2 (en) | Refill of implantable fluid delivery devices based on therapeutic fluid expiration | |
EP1501572B1 (en) | Patient controlled activation with implantable drug delivery devices | |
US9737660B2 (en) | Drug infusion device with controllable valve | |
US20140207122A1 (en) | Drug Delivery Safety System | |
US8622998B2 (en) | Automated catheter length determination for implantable fluid delivery device | |
WO2007051139A2 (en) | Diabetes management systems and methods | |
US10556060B2 (en) | Drug delivery programming techniques | |
US20110264034A1 (en) | Medical therapy modification authorization techniques | |
EP3742449A1 (en) | System and method for incorporating exercise into closed-loop diabetes therapy | |
US20090137987A1 (en) | Method and apparatus for multi-input stepwise infusion prescription | |
US20110166522A1 (en) | Accumulator for therapeutic fluid delivery devices | |
US20020151875A1 (en) | Patient activated administration of drug bolus from implantable drug delivery system | |
US9180282B2 (en) | Implantable drug delivery system having periodic drug delivery regimen to avoid granulomas | |
EP2224992A1 (en) | Patient controlled analgesia device and method of its use | |
DE10020494A1 (en) | Implantable, automatic dosing system comprises medicament storage and dosing pump with remotely programmed memory for safe limitation of dosage, while allowing limited freedom of self-administration | |
EP2187995B1 (en) | Implantable therapeutic substance delivery system with catheter access port block |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552) Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20220817 |